2000 Press Releases
Molecular Devices announces the completion of its acquisition of LJL BioSystems
Sunnyvale, CA - August 30, 2000 - Molecular Devices Corporation (Nasdaq: MDCC) today announced that it has completed its acquisition of LJL BioSystems, Inc. (Nasdaq: LJLB). The stockholders of both companies have approved the transaction, and all regulatory requirements and other conditions have been satisfied. Under the merger agreement announced on June 8, 2000, Molecular Devices will issue approximately 4.45 million shares of its common stock in the transaction (valued at approximately $348.8 million based on the closing price of Molecular Devices’ common stock on August 30, 2000) and assume options and warrants to acquire approximately 675,000 additional shares. The merger will be accounted for as a pooling of interests.
• • • • • • • • • • • • • • • • • • • • • • • •
About Molecular Devices. Molecular Devices Corporation is a leading developer of high-performance, bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Molecular Devices’ systems enable pharmaceutical and biotechnology companies to leverage advances in genomics and combinatorial chemistry by facilitating the high throughput and cost effective identification and evaluation of drug candidates. Molecular Devices’ instrument systems are based on its advanced core technologies which integrate its expertise in engineering, molecular and cell biology and chemistry and are fundamental tools for drug discovery and life sciences research. Additional information can be found at www.moldev.com.
Forward Looking Statements. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "would" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the risks and other factors described in the company’s Registration Statement on Form S-4 filed in connection with the acquisition of LJL BioSystems and the company’s most recent Form 10-K and other periodic filings with the Securities and Exchange Commission.
Molecular Devices introduces two new liquid handling products
Sunnyvale, California —Monday May 1, 2000. Molecular Devices Corporation (Nasdaq: MDCC), a leader in innovative solutions for drug discovery and life science research, today announced the addition of two new products to its Skatron line of liquid handling systems. The Embla 96/384 well washer and SkanWasher 400 automatic microplate washer will provide drug discovery and life science researchers with more effective liquid handling solutions, enabling them to decrease both the time and cost of discovering new drugs.
The new Embla 96/384 well washer can be used with either 96-well microplates or 384-well microplates for high throughput screening applications. As a result of its flexibility, the new Embla complements the Company’s full line of MaxLine ™ microplate readers and FLIPR ® systems. In addition, new functionality has been added that enables the user to fine-tune dispense speed and volume, allowing the system to address a broader range of assays and cell-based applications.
The redesigned SkanWasher 400 automatic 96-well microplate washer offers life science researchers a compact, economical solution for their washing needs. The improved SkanWasher 400 occupies minimal benchtop space and offers fast, effective washing of 96-well microplates for ELISAs and most cell-based applications. The new compact design of the SkanWasher 400 also offers a four-fold decrease in noise level for gentle, quiet operation.
• • • • • • • • • • • • • • • • • • • • • • • •
Molecular Devices Corporation is a leading developer of high-performance, bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company’s systems enable pharmaceutical and biotechnology companies to leverage advances in genomics and combinatorial chemistry by facilitating the high throughput and cost effective identification and evaluation of drug candidates. The Company’s instrument systems are based on its advanced core technologies which integrate its expertise in engineering, molecular and cell biology and chemistry and are fundamental tools for drug discovery and life sciences research.
This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company’s SEC reports, including its Annual Report on Form 10K for the year ended December 31, 1999.
Molecular Devices registered as an ISO 9001 company
Molecular Devices Corporation has been registered by TUV Rheinland of North America, Inc. as an ISO 9001 company (certificate registration #743009717). Molecular Devices Quality Policy Statement: Based on the principles of continuous improvement, Molecular Devices will meet or exceed agreed customer requirements every time.
|
